Introduction: Understanding Necrobiosis Lipoidica

Necrobiosis lipoidica (NL) is a rare, chronic granulomatous skin disorder of unknown etiology, though it is strongly associated with diabetes mellitus—particularly type 1 diabetes. The condition typically presents as well-defined, red-brown to yellowish plaques, most commonly on the pretibial region, but it can also involve the ankles, arms, trunk, or scalp. The name derives from the histological findings of necrobiosis (degeneration) of collagen and deposition of lipids. NL affects approximately 0.3% of patients with diabetes, with a female predominance and peak incidence between ages 30 and 60.

While many cases remain asymptomatic or only mildly symptomatic, a subset of patients develops severe, painful ulcerations that are notoriously difficult to treat. These ulcerations can become infected, cause significant morbidity, and dramatically reduce quality of life. Standard topical and systemic therapies often yield suboptimal results in severe or refractory cases, leading clinicians to explore biologic therapies—a class of targeted immunomodulators that have transformed the management of numerous inflammatory and autoimmune diseases. This article examines the role of biologic therapies in severe necrobiosis lipoidica, reviewing the underlying mechanisms, available evidence, clinical considerations, and future directions.

Pathophysiology and Clinical Features

Histology and Immune Dysregulation

Histopathologic examination of NL lesions reveals a palisading granulomatous infiltrate composed of histiocytes and giant cells surrounding areas of degenerate collagen (necrobiosis). There is also associated vasculopathy with endothelial swelling, basement membrane thickening, and sometimes thrombotic occlusion of small vessels. These findings suggest a primary inflammatory process targeting the dermal microvasculature, leading to ischemic damage and tissue degeneration. The exact trigger is unknown, but it is hypothesized that hyperglycemia, advanced glycation end-products, and oxidative stress in diabetes induce an aberrant immune response involving T lymphocytes, macrophages, and pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF‑α), interleukin‑1 (IL‑1), and IL‑6.

Clinical Presentation and Natural History

Lesions typically begin as small, firm, red-brown papules that expand slowly into oval or irregular plaques with a waxy, atrophic center and an elevated, violaceous border. The surface may become shiny, telangiectatic, and ulcerated in up to 35% of cases. Ulcerations are often deep, painful, and slow to heal, predisposing patients to secondary infections, cellulitis, and rarely squamous cell carcinoma arising in chronic wounds. Although spontaneous remission occurs in roughly 19% of patients, the disease typically follows a relapsing-remitting or progressive course.

Importantly, necrobiosis lipoidica is not pathognomonic for diabetes: up to 25% of patients have no evidence of diabetes at diagnosis, though a proportion may develop it later. Therefore, all patients with NL should be screened for glucose intolerance and followed longitudinally.

Traditional Treatment Approaches

Topical and Intralesional Therapies

First-line management of non-ulcerated NL includes topical corticosteroids (e.g., clobetasol propionate 0.05%) and topical calcineurin inhibitors such as tacrolimus ointment. Intralesional corticosteroid injections (e.g., triamcinolone acetonide) can reduce inflammation and halt progression but are limited by the risk of atrophy. For ulcerated lesions, wound care with hydrocolloid dressings, antimicrobial agents, and growth factor preparations is essential. However, these methods rarely produce complete resolution and do not address the underlying immune dysregulation.

Systemic Immunosuppressants

When topical therapy fails or disease is extensive, systemic agents are employed. Corticosteroids (prednisone), mycophenolate mofetil, cyclosporine, methotrexate, and hydroxychloroquine have all been used with variable success. A 2019 systematic review of 75 studies found that only 25–40% of patients treated with conventional immunosuppressants achieved complete or significant improvement. Moreover, these drugs carry substantial side-effect profiles—particularly with long-term use—including osteoporosis, hypertension, nephrotoxicity, hepatotoxicity, and increased infection risk. The frequent lack of durable response and the need for prolonged therapy often necessitate escalation to more targeted biologics.

Phototherapy and Photodynamic Therapy

Psoralen plus ultraviolet A (PUVA) and narrowband UVB have been reported to improve NL lesions in small case series, possibly by modulating local immune responses and promoting collagen remodeling. However, phototherapy is logistically burdensome and carries a risk of photoaging and carcinogenesis. Photodynamic therapy with aminolevulinic acid has also been tried but lacks robust evidence.

The Emergence of Biologic Therapies

Biologic therapies are genetically engineered proteins that specifically inhibit immune pathways implicated in inflammatory diseases. The rationale for using biologics in necrobiosis lipoidica stems from the recognition of TNF‑α as a key driver of granuloma formation and inflammation. TNF‑α inhibitors block the binding of TNF‑α to its receptors, thereby reducing cellular infiltration, cytokine production, and tissue destruction. Other biologics targeting interleukins (e.g., IL‑12/23, IL‑17) or other immune checkpoints are also being investigated.

Mechanisms of Action

Anti-TNF‑α agents (e.g., adalimumab, etanercept, infliximab) neutralize soluble and membrane-bound TNF‑α, interrupting the inflammatory cascade. Adalimumab is a fully human monoclonal IgG1 antibody administered subcutaneously; etanercept is a soluble TNF receptor fusion protein; infliximab is a chimeric monoclonal antibody given intravenously. All three reduce granulomatous inflammation and have been used effectively in granulomatous diseases such as sarcoidosis and Crohn’s disease, making them logical candidates for NL.

Newer biologics such as ustekinumab (targeting IL‑12/23) and secukinumab (targeting IL‑17A) have shown efficacy in psoriasis and psoriatic arthritis, and anecdotal reports suggest benefit in NL. The IL‑12/23 pathway is crucial for Th1/Th17 differentiation, which may be involved in NL pathogenesis. However, data remain limited.

Evidence for Biologics in Necrobiosis Lipoidica

The evidence base for biologics in NL consists primarily of case reports, small case series, and one retrospective cohort study. No large randomized controlled trials have been published, which limits the strength of recommendations.

  • Adalimumab: The most frequently reported biologic. A 2020 multicenter retrospective study of 32 patients found that adalimumab (usually 40 mg every other week after a loading dose) led to complete healing of ulcerations in 53% of patients and significant improvement in an additional 22% within 16 weeks. Response was maintained in most patients over 12 months of follow-up. Similarly, several case reports document dramatic improvement in refractory ulcerated NL after initiating adalimumab.
  • Etanercept: A few case reports and a small open-label pilot (n=6) showed moderate improvement in plaque size and tenderness, but ulcer healing was less consistent than with adalimumab. One study noted that etanercept 50 mg twice weekly reduced biomarkers of inflammation but did not achieve complete remission in refractory cases.
  • Infliximab: Intravenous infliximab (5 mg/kg at weeks 0, 2, and 6, then every 8 weeks) has been reported to induce rapid improvement in severe, treatment-resistant NL. In a case series of 7 patients, 4 had complete ulcer closure within 12 weeks. However, infusion reactions and the need for hospital-based administration limit its practicality.
  • Ustekinumab: A small series of 5 patients with NL and concomitant psoriasis reported improvement in both skin conditions. Ustekinumab (45 or 90 mg subcutaneously every 12 weeks after loading) led to complete resolution of NL plaques in 2 patients and partial improvement in 2 others.
  • IL-17 inhibitors: Case reports of secukinumab and ixekizumab show potential, but numbers are too small to draw conclusions.

Overall, the available evidence suggests that anti-TNF‑α agents—especially adalimumab—are the most promising biologic therapy for severe or ulcerated necrobiosis lipoidica. Response rates in the range of 50–75% are encouraging, particularly in a disease that often fails conventional treatments.

Practical Considerations for Biologic Use

Before initiating a biologic, patients must undergo screening for latent tuberculosis, hepatitis B and C, and other chronic infections, because TNF‑α inhibitors can reactivate latent infections. Baseline complete blood count, liver and renal function tests, and pregnancy testing (if applicable) are standard. Vaccinations should be updated as appropriate, particularly influenza and pneumococcal vaccines. Biologics should be avoided in patients with active infections, demyelinating diseases, or moderate-to-severe heart failure.

Adalimumab and etanercept are typically self-administered subcutaneously, while infliximab requires intravenous infusion in a clinic or hospital. The cost of biologics is high—adalimumab averaged over $50,000 per year in the United States—though insurance coverage and patient assistance programs can mitigate this burden. Treatment duration is usually at least 6 months before evaluating response; if effective, maintenance therapy may be continued for 1–2 years or longer, with periodic reassessment.

Challenges and Limitations of Biologic Therapy in NL

High Cost and Accessibility

The financial burden of biologics is a major barrier, particularly for patients without adequate insurance. Even with coverage, prior authorization and high copayments can delay or prevent treatment. In countries with public health systems, access may be limited to patients who meet strict criteria (e.g., severe, ulcerated NL with failure of multiple conventional therapies). Biosimilars such as adalimumab-atto may reduce costs, but their specific efficacy in NL has not been studied.

Adverse Effects and Safety Profile

Common side effects of anti-TNF‑α agents include injection site reactions (e.g., redness, swelling, pain), headache, and increased susceptibility to upper respiratory tract infections. Serious adverse events, though rare, include serious infections (especially tuberculosis), opportunistic infections, malignancy (particularly lymphoma), demyelinating syndromes, and exacerbation of heart failure. In the largest NL series to date, 2 of 32 patients discontinued adalimumab due to infection (pneumonia and cellulitis). No deaths were reported.

Long-term safety data in NL are lacking, but extrapolation from larger populations (e.g., rheumatoid arthritis, psoriasis) indicates that the risk-benefit ratio is acceptable when patients are carefully selected and monitored. Regular follow-up with laboratory tests and clinical evaluation is essential.

Lack of Standardized Protocols

Because no prospective trials have been conducted in NL, dosing regimens, optimal duration, and tapering strategies are based on expert opinion and extrapolation from other granulomatous diseases. Some clinicians use the same dosing as for psoriasis (e.g., adalimumab 80 mg loading then 40 mg every other week), while others adopt the higher doses used for Crohn’s disease. There is also no consensus on how to manage patients who lose response over time (secondary failure)—options include dose escalation, switching to a different biologic class, or adding a conventional immunosuppressant.

Future Directions and Research Needs

Biomarkers and Patient Selection

Identifying predictors of response to biologics would improve patient selection and cost-effectiveness. Potential biomarkers under investigation include serum levels of TNF‑α, soluble TNF receptors, and other inflammatory cytokines, as well as histologic features (e.g., degree of granulomatous inflammation, vascular changes). Genetic profiling might also help stratify patients. However, due to disease rarity, large-scale biomarker studies are challenging.

Combination Strategies

Combining biologics with other treatments may enhance efficacy and allow dose reduction. For example, adalimumab plus methotrexate has shown synergy in rheumatoid arthritis and could be explored in NL. Topical wound care and negative-pressure wound therapy might accelerate healing of ulcerated lesions when combined with systemic biologic therapy. Photodynamic therapy or laser treatment could be used adjunctively for non-ulcerated plaques.

New Biologic Targets

Recent insights into the immunopathogenesis of NL suggest potential roles for additional targets. The IL‑23/Th17 axis is increasingly implicated in granulomatous inflammation, making agents such as guselkumab (IL‑23 inhibitor) or bimekizumab (IL‑17A/F inhibitor) attractive candidates. JAK-STAT inhibitors like tofacitinib or upadacitinib—which block multiple cytokine pathways—could also hold promise, especially for patients with concomitant diabetes, as some JAK inhibitors are being studied for diabetic kidney disease.

Registry and Collaborative Studies

The rarity of NL makes randomized controlled trials difficult. International collaborative efforts to establish a patient registry and conduct multicenter prospective observational studies are urgently needed. Such registries could collect standardized data on disease characteristics, treatment outcomes, adverse events, and quality of life. Bayesian adaptive trial designs or n-of-1 trials might also be feasible in this context.

Practical Tips for Clinicians

  • Diagnosis: Confirm NL with biopsy if clinical doubt exists; rule out concomitant diabetes or prediabetes.
  • Step therapy: Begin with topical corticosteroids and wound care. If no improvement after 8–12 weeks, consider intralesional steroids or phototherapy. For progressive/ulcerated disease, advance to systemic immunosuppressants or biologics.
  • Biologic initiation: Screen for infections, consider adalimumab as first-line biologic based on evidence; obtain baseline labs and vaccinations.
  • Monitoring: Assess clinical response every 8–12 weeks; monitor for infections, injection site reactions, and laboratory abnormalities.
  • Referral: Consider dermatology referral for all cases of necrobiosis lipoidica; involve a wound care specialist for ulcers.
  • Patient education: Discuss realistic expectations, cost, need for adherence, and potential side effects. Encourage diabetes management if applicable.

Conclusion

Necrobiosis lipoidica, particularly when severe and ulcerated, poses a therapeutic challenge. Traditional treatments have limited efficacy, and the chronic inflammatory nature of the disease calls for more targeted immunomodulation. Biologic therapies—especially TNF‑α inhibitors like adalimumab—have emerged as a valuable option, with case series showing substantial improvements in ulcer healing and disease control for patients who have failed conventional therapies. While the evidence base remains limited and the cost and safety concerns require careful management, biologics represent a significant advance in the care of severe necrobiosis lipoidica.

Future research should focus on conducting prospective trials or large collaborative registries to define optimal patient selection, treatment protocols, and long-term outcomes. For now, clinicians should consider biologics for patients with refractory, ulcerated, or rapidly progressive NL, after ruling out contraindications and discussing risks and benefits. With continued investigation and clinical experience, biologic therapies may become a cornerstone of management for this difficult condition.

For more information on necrobiosis lipoidica and its management, consult a recent review in the Journal of Clinical Medicine, the American Academy of Dermatology patient page, and DermNet’s comprehensive resource. Clinical trial updates may be found at ClinicalTrials.gov.